The Wegovy pill (oral semaglutide 25 mg): uses, dosing, side effects and cost

The Wegovy pill is oral semaglutide, a once-daily GLP-1 tablet from Novo Nordisk that the FDA approved on 22 December 2025 for long-term weight reduction and to lower heart attack and stroke risk in adults. It steps up from 1.5 mg to a 25 mg maintenance dose and is taken fasting with a little water.

Quick facts

Active ingredient
Semaglutide, co-formulated with the absorption enhancer salcaprozate sodium (SNAC) (Wegovy label)
Maker
Novo Nordisk
FDA approval
22 December 2025, NDA 218316 (FDA approval letter); label last revised March 2026
Approved for
Long-term weight reduction in adults with obesity, or overweight plus a weight-related condition; cutting major cardiovascular events in adults with heart disease
Form
Tablet, swallowed whole on an empty stomach with up to 4 oz of plain water
How often
Once a day, in the morning
Dose strengths
1.5 mg, 4 mg, 9 mg and 25 mg; 25 mg is the maintenance dose
Boxed warning
Yes: thyroid C-cell tumors in rodents; MTC in you or a relative, or MEN 2, rules it out
Self-pay price
1.5 mg $149/month; 4 mg $199; 9 mg and 25 mg $299 each (NovoCare Wegovy page, checked 5 Oct 2026)
Generic available?
No US generic of Wegovy tablets

What it is

Wegovy tablets are the oral form of Wegovy. They hold the same molecule as the weekly Wegovy pen, semaglutide, in a daily tablet built around salcaprozate sodium (SNAC), an absorption enhancer that lets a peptide get through the stomach wall before it is broken down (Wegovy label, section 12.3). Each tablet contains only semaglutide, SNAC and magnesium stearate.

The FDA approved the tablets under new drug application 218316, in a letter signed on 22 December 2025, and Novo Nordisk said pharmacies and selected telehealth services would have them from early January 2026. The tablets and the pen now share one prescribing information document, most recently revised in March 2026.

The Wegovy pill is not Rybelsus, Novo Nordisk's other semaglutide tablet, which is a type 2 diabetes medicine. The two are not interchangeable, and the Wegovy label advises against taking Wegovy with any other semaglutide product or GLP-1 medicine. Oral semaglutide vs. oral Wegovy sets them side by side.

How it works

Semaglutide is a GLP-1 receptor agonist: an engineered version of the gut hormone glucagon-like peptide-1, sharing 94% of its sequence (Wegovy label, 12.1). It reduces calorie intake, most likely through appetite, and slows stomach emptying. It also prompts insulin release and lowers glucagon when blood sugar is raised.

The hard part for a tablet is absorption. Only about 1% to 2% of the semaglutide swallowed reaches the bloodstream, mostly through the stomach, with a peak about an hour after the dose (label, 12.3). That explains the large daily dose and why food, other drinks and the post-dose wait all matter. In adults without diabetes, 25 mg tablets gave average steady-state levels of about 77 nmol/L, close to the 75 nmol/L seen on the 2.4 mg weekly injection, though tablet levels varied more between people.

Approved uses

The label approves Wegovy tablets for two uses, each alongside a reduced-calorie diet and more physical activity:

  • Weight reduction and keeping it off long term in adults with obesity, or in adults with overweight plus at least one weight-related condition. Its trial, OASIS 4, enrolled a BMI of 30 or more, or 27 or more with a condition such as high blood pressure or abnormal cholesterol.
  • Cutting the risk of a major cardiovascular event, meaning a heart attack, stroke or cardiovascular death, for adults who already have cardiovascular disease and also have obesity or overweight.

The injection's other approvals, for adolescents aged 12 and over and for MASH liver disease, do not extend to the tablets. Adults with type 2 diabetes were left out of the tablet's weight-loss trial, so that use is unstudied.

What the evidence shows

OASIS 4 (Study 7 in the label; NEJM 2025). 307 adults without diabetes, averaging 106 kg, took 25 mg tablets or placebo for 64 weeks with diet and activity counselling. Counting everyone randomized, body weight changed by an average of −13.6% on the tablet and −2.4% on placebo in the label's analysis; the published paper gives −2.2% for placebo. In the label table, 76.3% on the tablet lost at least 5% of their weight, 47% lost at least 15% and 27.9% lost at least 20%, against 31.3%, 5.5% and 3.1% on placebo. Waist size fell by 12.2 cm against 2.8 cm. These are group averages, and individual results spread widely around them.

SELECT (Study 1 in the label). The cardiovascular indication is supported in the label by a trial of the 2.4 mg weekly injection in 17,604 adults with heart disease and no diabetes. A first major cardiovascular event occurred in 6.5% on semaglutide and 8% on placebo (hazard ratio 0.80). The label contains no cardiovascular outcomes trial of the 25 mg tablet.

No trial has compared the tablet directly with the injection or with Foundayo.

Dosing overview

One tablet each morning on an empty stomach, with no more than 4 ounces of plain water, followed by at least 30 minutes without food, drinks or other oral medicines. The label's schedule rises every 30 days: 1.5 mg on days 1 to 30, 4 mg on days 31 to 60, 9 mg on days 61 to 90, and 25 mg from day 91. If a step is poorly tolerated, the prescriber may delay the next one. A missed tablet is skipped, never doubled. Switching rules, special populations and the maximum are on the Wegovy pill dosage page; the morning routine is on how to take the Wegovy pill.

Side effects overview

Digestive effects dominate. In OASIS 4, 74.0% of people on the 25 mg tablet reported a gastrointestinal adverse event against 42.2% on placebo (NEJM 2025), mostly mild to moderate and concentrated during dose increases. The label says the tablet's common reactions resembled those of the 2.4 mg injection, where nausea reached 44%, diarrhea 30% and vomiting 24%. For tablets specifically it records altered skin sensation (dysesthesia) in 5% against none on placebo, gallstones in 2.5% against 1%, and severe gastrointestinal reactions in 2% against 0%. 6.9% stopped the tablet because of adverse reactions, against 5.9% on placebo.

Rarer serious risks include pancreatitis, kidney injury from dehydration, allergic reactions and aspiration under anesthesia. Rates and warning signs are on Wegovy pill side effects.

Who should not take it

Wegovy is contraindicated if you or a close relative has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia type 2 (MEN 2), and after any past serious allergy to semaglutide or a tablet ingredient. It is not recommended with severe gastroparesis, alongside another semaglutide product or GLP-1 medicine, or while breastfeeding, because SNAC reaches breast milk. It should be stopped once a pregnancy is recognised, and at least 2 months before a planned one. The tablets are not approved for anyone under 18. A history of pancreatitis, gallbladder disease, diabetic eye disease or kidney problems is worth raising with the prescriber before starting.

Cost and access

Novo Nordisk lists the pill at $1,349.02 per 30-tablet bottle (NovoCare Wegovy page, checked 5 Oct 2026). Paying cash with the savings offer, the first bottle (1.5 mg) is $149, the 4 mg bottle $199, and each 9 mg or 25 mg bottle $299 (same page). With commercial insurance, the copay can drop to $25, with savings capped at $100 a month; government beneficiaries are excluded. For Medicare Part D, the temporary Medicare GLP-1 Bridge charges $50 a month for qualifying members until the end of 2027, subject to prior authorization (wegovy.com, checked 5 Oct 2026).

The Wegovy pill is not sold or filled by Temi. Its physicians can instead prescribe Foundayo, an FDA-approved daily GLP-1 tablet whose 0.8 mg starting month costs $149 from LillyDirect (usetemi.com/medications/foundayo, checked 5 Oct 2026). Temi's compounded semaglutide pill is a separate preparation that is not FDA-approved. Full figures: Wegovy pill cost.

More on this medication

Frequently asked questions

Is the Wegovy pill FDA approved?

Yes. The FDA approved Wegovy (semaglutide) tablets on 22 December 2025 under new drug application 218316, both for long-term weight reduction in adults with obesity or overweight plus a weight-related condition and for reducing major cardiovascular events in adults with heart disease. The current prescribing information, which the tablets share with the Wegovy injection, was revised in March 2026 and is published on the FDA's Drugs@FDA database.

Is the Wegovy pill as effective as the Wegovy shot?

They have never been tested against each other. In separate placebo-controlled trials reported in the label, the 25 mg tablet produced an average 13.6% weight loss at 64 weeks (OASIS 4), and the 2.4 mg injection produced 14.9% at 68 weeks (STEP 1, Study 2). The label also reports similar average blood levels for the two in adults without diabetes, but the tablet's levels vary more between individuals.

Is the Wegovy pill the same as Ozempic?

It contains the same active ingredient, semaglutide, but it is a different product. Ozempic is a once-weekly injection prescribed for type 2 diabetes. The Wegovy pill is a once-daily tablet with SNAC, approved for weight reduction and cardiovascular risk reduction. The Wegovy label advises against using it together with any other semaglutide product, which includes Ozempic, so the two are not combined.

Can you take the Wegovy pill if you have type 2 diabetes?

It is not ruled out, but the evidence is thinner. The label says the tablets were not studied for weight reduction in adults with type 2 diabetes, and that average semaglutide levels on 25 mg tablets were lower in people with diabetes (about 44 nmol/L) than on the 2.4 mg injection (about 68 nmol/L). For an inadequate response, the label suggests considering other options, including the injection.

Does Medicare cover the Wegovy pill?

Medicare's temporary GLP-1 Bridge prices every Wegovy pill and pen strength at $50 a month for qualifying Part D members, running July 2026 through December 2027 (wegovy.com, checked 5 Oct 2026). The prescriber must submit a prior authorization, and the patient must meet clinical criteria and be enrolled in a qualifying drug plan. Manufacturer savings cards exclude government beneficiaries.

How long do people stay on the Wegovy pill?

The label frames it as long-term treatment: the approved use is to reduce excess weight and maintain that reduction over time, and it sets no end date. OASIS 4 treated people for 64 weeks. After the last 25 mg tablet, semaglutide stays in the circulation for about 5 to 7 weeks, according to the label. Whether and when to stop is a decision to make with the prescriber.

Get started

Start online, and a licensed physician reviews your request

A short online questionnaire is the first step. No appointments and no insurance needed.

A licensed physician reviews every request. Nothing on this page is a prescription.

The revolution will be emailed.

Once a week, roughly.

We're taking the fight to a corrupt and broken health insurance system. Join up.

Get Temi's newsletter by email. Unsubscribe anytime. Privacy policy